arrow
E

Emanuela Ferraro

irccs european institute of oncology
H指数:18
被引数:2,250

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title

口服选择性雌激素受体降解剂(SERDs)用于治疗激素受体阳性、HER2阴性乳腺癌

2026-05-011
PRE
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer

乳腺癌的同源重组缺陷和半合子驱动抵抗

Nature
IF48.5
2026-03-040
OAAI
Public health impact of nirsevimab and reduction of RSV hospitalisation in all infants: early real-world data from Tuscany (Italy) in the 2024–25 RSV season

尼塞维马单抗的公共卫生影响及对所有婴儿RSV住院率的降低:2024–25年RSV流行季来自意大利托斯卡纳地区的早期真实世界数据

2025-11-030
OAAI
RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer

RSC4All 作为一种机器学习列线图,用于预测 HR+/HER2- 淋巴结阴性早期乳腺癌的 RSClin™ 结果

2025-10-070
OAAI
Serotype 3 invasive pneumococcal disease in Tuscany across the eras of conjugate vaccines (2005–2024) and anthropic-driven respiratory virus fluctuations

C群侵袭性肺炎球菌病在托斯卡纳地区,跨越结合疫苗时代(2005–2024年)及人类活动驱动的呼吸道病毒波动

2025-06-170
OA
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials

年龄对早期临床试验中研究的新型癌症药物安全性和有效性的影响

2024-08-012
PRE
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+breast cancer leptomeningeal metastases

HER2乳腺癌脑膜转移患者鞘内注射曲妥珠单抗与替代给药途径的HER2-targeted治疗

BREAST
IF7.9
2023-06-0115
OAAI